Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meihua Dianshe Wan is a traditional Chinese medicine (TCM) manufactured by Liaoning Jindan Pharmaceutical. It is an approved pharmaceutical product in China, traditionally used for its potent detoxification, anti-inflammatory, and analgesic properties. The formulation is primarily indicated for the treatment of 'heat-toxin' related conditions, including severe sore throat (pharyngitis), boils, carbuncles, and the early stages of breast abscesses (mastitis). The complex mixture typically includes ingredients such as Venenum Bufonis (toad venom), Calculus Bovis (ox gallstone), and Moschus (musk), which are known in pharmacological studies to exhibit anti-inflammatory and antimicrobial activities. It is administered orally as small pills.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meihua dianshe wan.